Hyperglycosylated hCG and Its Free ß-Subunit Drives Malignancy
DOI:
https://doi.org/10.6000/1927-7229.2018.07.03.4Keywords:
Hyperglycosylated hCG, hCG and Malignancy.Abstract
Tumor marker studies were conducted measuring 2,277 malignancies using a cut-off of 3 fmol/ml. As found 110 of 110 trophoblastic malignancies or 100% were positive for ß-core fragment an hCG serum degradation product. Just 949 of 2167 (44%) of non-trophoblastic or other cancers were positive using this 3 fmol/ml cut-off. When the cut-off of the assay was lowered to 0.1 fmol/ml, or lowered by 30-fold 100% of non-trophoblastic or other cancers were detected, or all cancers were detected.
What do cancers secrete. Cancer were tested with three immunoassays, Immulite total hCG, B152 hyperglycosylated hCG and FBT11 free ß-subunit, serum of 34 trophoblastic cancers and 32 non-trophoblastic cancers were tested. A total of 34 of 34 trophoblastic cancer produced primarily hyperglycosylated hCG (B152 hyperglycosylated assay 96%±12% of Immulite), and 32 of 32 non-trophoblastic cancers produced primarily hyperglycosylated hCG free ß-subunit (B152 hyperglycosylated assay 102%±6.2% of Immulite, FBT11 free ß-subunit assay 128%±10% of Immulite).
Seven independent laboratories each showed with a wide mixture of cancers (patient tissue and cancer cell lines) that ß-subunit promoted malignancy (cell growth, cell invasion and blockage of apoptosis) in cancer cells. I then showed that hyperglycosylated hCG and its ß-subunit promoted malignancy in 10 different cancer cell lines.
I then tied my data and the seven independent laboratory data together and concluded that hyperglycosylated hCG and its ß-subunit drove malignancy in all or most cancers.
References
Organisation mondial de la Santé. Maladies non transmissibles. Consulté à partir du site de l’Organisation mondiale de la Santé: http://www.who.int/topics/ noncommunicable_diseases/fr,2015.
Breslow N, Chan C, Dhom G, Drury R, Franks L, Gellei B, Lee Y, Lundberg S, Sparke B, et Sternbya N. Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France. International Journal of Cancer 1977; 20(5): 680-688. https://doi.org/10.1002/ijc.2910200506
Chauvet B, Villers A, Davin J-L, Nahon S. Actualités sur le dépistage, le diagnostic et le traitement des cancers de prostate. Bulletin du Cancer 2002; 89(1): 37-45.
Carroll P, Coley C, Mcleod D, Schellhammer P, Sweat G, Wasson J, Zietman A, et Thompson I. Prostate-specific antigen best practice policy—part I: early detection and diagnosis of prostate cancer. Urology 2001; 57(2): 217-224. https://doi.org/10.1016/S0090-4295(00)00993-6
D’Amico AV, Anthony V, Whittington R, Malkowicz S, Renshaw A, TomaszewskI J, Bentley C, Schultz D, Rocha S, Wein A, et Richie J-P. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology 2001; 58(3): 406-410. https://doi.org/10.1016/S0090-4295(01)01204-3
Villers A, Chautard D. PSA libre: l’utilisation en routine est prématurée pour le dépistage du cancer de la prostate. Progrès en Urologie 2000; 10(4): 618-21.
Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A, Richie J-P, Walsh P, Scardino P, et Lange P. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279(19): 1542-1547. https://doi.org/10.1001/jama.279.19.1542
Ravery V, Javerliat I, Toublanc M, Boccon-Gibod L, Delmas V, Boccon-Gibod L. Caractéristiques des cancers prostatiques chez les français d’origine afro-antillaise. Progrès en Urologie 2000; 10(2): 231-236.
Catalona W, Richie J-P, Ahmann F, M’liss A, Scardino P, Flanigan R, Dekernion J, Ratliff L, Kavoussi L, et Dalkin L. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. The Journal of Urology 1994; 151(5): 1283-1290. https://doi.org/10.1016/S0022-5347(17)35233-3
Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. The Journal of Urology 2000; 164(2): 393-396. https://doi.org/10.1016/S0022-5347(05)67368-5
Baudin B. Les tests de diagnostic rapide en biochimie médicale: intérêts, limites et dangers. Revue Francophone des Laboratoires 2015; 2015(475): 31-38. https://doi.org/10.1016/S1773-035X(15)30247-1
Nkwenkeu SF. Evaluation des politiques publiques de santé: une analyse économique appliquée au Cameroun 2014.
Quatrième Enquête Camerounaise Auprès des Ménages (ECAM 4): Tendance, profil et déterminants de la pauvreté au Cameroun entre 2001-2014. Institut national de la statistique, déc-2015.
profil des pays pour le cancer. organisation mondiale de la santé, 2014.
Amiel J, Chevallier D, Peyrottes A, Benoliel J, Toubol J. Corrélations anatomoclinique et biologique (PSA-PAP) dans la pathologie prostatique: à propos de 150 observations. Journal d’urologie 1990; 96(4): 199-201.
Fulla Y, Noel M, Le Brun G. Optimisation de l’utilisation du PSA. Médecine Nucléaire 2008; 32(1): 31-40. https://doi.org/10.1016/j.mednuc.2007.11.004
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Guan Min Lai, Jen-Tsun Lin , Cheng-Shyong Chang , Metastatic Bone Marrow Tumors Manifested by Hematologic Disorders: Study of Thirty-Four Cases and Review of Literature , Journal of Analytical Oncology: Vol. 3 No. 4 (2014)
- Antonio Carrera Torres, Ángel Martínez-Sahuquillo Márquez, Javier Fernández Farhall, María José Cobos Fuentes, Isabel Gallardo Castillo, Efficacy of Chemiluminescence (ViziLite™) as a Screening Method in the Detection of Clinically Suspicious Oral Cancerous and Precancerous Lesions , Journal of Analytical Oncology: Vol. 2 No. 3 (2013)
- Tatiana Levkovich, Theofilos Poutahidis, Kelsey Cappelle, Mark B. Smith, Allison Perrotta, Eric J. Alm , Susan E. Erdman , ‘Hygienic’ Lymphocytes Convey Increased Cancer Risk , Journal of Analytical Oncology: Vol. 3 No. 3 (2014)
- Daiki Taniyama, Tsuyoshi Torii, Junichiro Kuga, Yoriko Dodo, Hitomi Tanaka, Yoshimasa Sueda , Kiyomi Taniyama , A Case Report of Visual Disturbance Caused by Thrombosis of the Superior Sagittal Sinus , Journal of Analytical Oncology: Vol. 3 No. 1 (2014)
- Kenji Ina, Yuu Hosoe, Kazuhiro Ito, Miho Tatematsu, Masako Sakakibara, Megumi Kabeya, Satoshi Kayukawa, Yoshihiro Ohta, A Retrospective Survey of Patients Undergoing Maintenance Hemodialysis vis-à-vis Cancer Prevalence , Journal of Analytical Oncology: Vol. 9 (2020)
- Cardile Venera , Avola Rosanna, C.E. Graziano Adriana, Madrid Alejandro, Russo Alessandra, Boldine Activates Intrinsic Apoptotic Pathway in DU-145 Androgen-Independent Prostate Cancer Cell Line , Journal of Analytical Oncology: Vol. 8 (2019)
- Hemant Krishna, Sidramesh Muttagi, Pranav Ingole, Pankaj Chaturvedi, Shovan Kumar Majumder, Tobacco Consumption Induced Changes in the Healthy Oral Mucosa and its Effect on Differential Diagnosis of Oral Lesions - A Clinical In Vivo Raman Spectroscopic Study , Journal of Analytical Oncology: Vol. 5 No. 3 (2016)
- Mariella Caffo, Gerardo Caruso, Valeria Barresi, Maria Angela Pino, Mario Venza, Concetta Alafaci, Francesco Tomasello, Immunohistochemical Study of CD68 and CR3/43 in Astrocytic Gliomas , Journal of Analytical Oncology: Vol. 1 No. 1 (2012)
- José Celso Ardengh, Eder Rios de Lima-Filho, Filadélfio Venco, Precursor Lesions of Pancreatic Cancer: A Current Appraisal on Diagnosis , Journal of Analytical Oncology: Vol. 1 No. 1 (2012)
- A. Bajwa, C. Stephen Foster, Diagnostic Testing of Primary Vitreo-Retinal Lymphoma , Journal of Analytical Oncology: Vol. 2 No. 3 (2013)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Laurence A. Cole, Hyperglycosylated hCG Drives Malignancy in Most or All Human Cancers: Tying All Research Together , Journal of Analytical Oncology: Vol. 7 No. 1 (2018)